JAK2 V617F VAF as a diagnostic and prognostic marker for polycythemia vera and thrombosis risk Published 2022-11-15 Download video MP4 360p Download video MP4 720p Recommendations 10:56 Identifying and Communicating Your Polycythemia Vera (PV) Symptoms 03:19 Targeting JAK2 V617F VAF in polycythemia vera & the efficacy of ropeginterferon alfa-2b 07:27 Smith Asks Witnesses About Financial Burden Of Long-COVID: ‘How’s It Working With Health Insurance?’ 03:03 The impact of salvage and bridging therapy on CAR T-cell therapy outcomes in B-ALL: an ITT analysis 06:35 Investigating the cardiovascular toxicities associated with bispecific T-cell engagers 08:27 How would you manage a young woman with thrombocytosis? 02:57 Favezelimab plus pembrolizumab in transplant-ineligible patients with R/R classical Hodgkin lymphoma 03:19 An efficacy sub-analysis from the ACE-536-MF-001 study of luspatercept for MF-related anemia 01:51 The use of BTK inhibitors in R/R and treatment-naïve patients with WM 06:16 What is Thalassemia? Types, Treatment and Symptoms 03:13 3 things to remember when diagnosing patients with MGUS 09:14 For Men only: Seriously...don't watch this if you're female 06:48 Key trials in multiple myeloma presented at ASH 2023: take home messages 01:57 Enhancing clinical care in LR-MDS: managing symptomatic/transfusion-dependent anemia 01:12 TrAVeRse: acalabrutinib + venetoclax and rituximab for treatment-naïve MCL 02:31 Improving patient outcomes and extending survival in CLL 09:59 Promising new drugs in MPN therapy 02:22 Real-world outcomes following dose reduction of first-line ibrutinib in patients with WM 04:27 The unmet needs in AL amyloidosis and limitations of the current SoC 12:08 What Foods Help Repair Kidneys? [BEST foods for Kidney Health & Diet] Similar videos 04:35 The role of JAK2 VAF testing in risk assessment and disease monitoring in MPNs 03:18 JAK 2 V617F Mutation Blood Test | What Is JAK 2 Mutation | Test For Polycythemia Vera | 02:50 Managing Polycythemia Vera: A Comprehensive Guide 11:19 POLYCYTHEMIA VERA Etiology Molecular pathogenesis of JAK2V617F mutation. JAK2 kinase 01:29 What is a JAK2 mutation? 03:49 Can JAK2V617F VAF variations help predict clinical and survival outcomes? 06:04 The need to improve diagnostic criteria in PV and other challenges in the field 02:34 JAK2 V617F Mutations (Myeloproliferative neoplasms (MPNs)): A blood disorder 02:30 The role of red cell mass measurement in the diagnosis of polycythemia vera 03:25 Understanding the Molecular Pathophysiology of Polycythemia Vera 52:18 9-24-20 - JAK2 The Future_ Updates in the Biology and Treatment of Myeloproliferative Neoplasms 01:30 Limitations of current risk stratification system models for polycythemia vera 10:20 New guidelines for the treatment and management of polycythemia vera 06:43 Should JAK2 VAF testing be implemented as routine in risk assessment and disease monitoring in MPN? 02:39 Targeting JAK2 V617F in MPNs with interferon alpha and arsenic trioxide 02:58 Unmet needs in polycythemia vera: improving symptoms & qualify of life 03:20 Current and emerging therapies for polycythemia vera 03:04 Genetic analyses for accurate diagnosis of blood cancer (Ann Lab Med) More results